Every year, the European Society for Medical Oncology Congress
brings together clinicians, researchers, and advocates to discuss the
latest cancer study results. We’re proud to present our coverage below.
Immunotherapy Keytruda for Early-Stage Triple-Negative Breast Cancer: Better pCR and Lower Recurrence Rates: ESMO 2019 Coverage
Peter Schmid, M.D., Ph.D.
Immunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage
Leisha Emens, M.D.
Plus Faslodex Improves Survival in Metastatic
Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of
George W. Sledge, Jr., M.D.
Inhibitor Plus Hormonal Therapy Should Be First Treatment for
Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer" ESMO
Dennis Slamon, M.D.
Where Are We With Immunotherapy for Breast Cancer? ESMO 2019 Coverage
Jennifer Litton, M.D.
Heard in the Halls Mini Episodes:
Breast Cancer Research Highlights -- Heard in the Halls: Voices From ESMO 2019
Anne White, BS
People Satisfied With Decision to Use Scalp Cooling, Even If
It's Not Effective -- Heard in the Halls: Voices From ESMO 2019
Conleth Murphy, M.D.